Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for Revolution Medicines (RVMD) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • Revolution Medicines' Depreciation and Depletion rose 25.00% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 11.67%. This contributed to the annual value of $6.2 million for FY2024, which is 24.00% up from last year.
  • Per Revolution Medicines' latest filing, its Depreciation and Depletion stood at $2.0 million for Q3 2025, which was up 17.65% from $1.7 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Depreciation and Depletion high stood at $2.0 million for Q3 2025, and its period low was $900,000 during Q1 2022.
  • For the 3-year period, Revolution Medicines' Depreciation and Depletion averaged around $1.5 million, with its median value being $1.5 million (2024).
  • Data for Revolution Medicines' Depreciation and Depletion shows a peak YoY skyrocketed of 33.89% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Revolution Medicines' Depreciation and Depletion stood at $1.2 million in 2022, then rose by 10.45% to $1.3 million in 2023, then grew by 7.69% to $1.4 million in 2024, then increased by 25.00% to $2.0 million in 2025.
  • Its Depreciation and Depletion was $2.0 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.